Measurement Algorithm Control, Optimization, and Performance Evaluation of the Vital USA GlucoseDetect

Diabetes Mellitus Clinical Trial

Official title:

Measurement Algorithm Control and Optimization With Subsequent Performance Evaluation of the Vital USA GlucoseDetect™ During a Standardized Meal Test in Patients With Diabetes Mellitus Type 1 and Type 2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04340648
• Other study ID #: VIT-NGM-001
• Status: Completed
• Phase: N/A
• Start date: June 3, 2019
• Est. completion date: November 30, 2019

Study information

• Verified date: April 2020
• Source: Sciema UG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Measurement Algorithm Control and Optimization with Subsequent Performance Evaluation of the Vital USA GlucoseDetect™ During a Standardized Meal Test in Patients with Diabetes mellitus Type 1 and Type 2

Description:

This study is a combined, open label, prospective, comparative single-center study.

The study is separated in 3 consecutive study parts. The first 2 study parts include 16 patients each. In the third study part 16 additional patients will be enrolled. Study part 1 and 2 will be used for optimization and validation of the measurement algorithms of the Vital USA biosensor. During the third study part with enrolment of 16 additional patients, the precision and accuracy of the final Vital USA biosensor algorithm will be demonstrated. The visit schedule for all participants of all 3 study parts will be exactly the same. In all groups of participants, the Vital USA non-invasive monitoring biosensor will be individually introduced and assigned. During the experimental study visit, a standardized meal will be given to the participants. Before and after the standardized meal, glucose, heart rate, and pO2 will be measured using the Vital USA monitoring biosensor at time-points -30, 0, 15, 30, 45, 60, 75, 90, 120, 150 and 180 min. The glucose measurements will be compared to capillary blood glucose measurements by YSI Stat 2300. Parallel measurements of the heart rate and the pO2 using a patient monitor will be compared to the device readings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: November 30, 2019
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Type 1 or Type 2 diabetic or healthy subject (50 % from each)

• Subjects who are able to complete informed consent form (by him/herself or by his/her guardian);

• 18 years old and above;

• Anatomically suitable finger in discretion of the investigator

Exclusion Criteria:

• Does not meet inclusion criteria;

• Any conditions that may hamper good visual contact between the finger or wrist and sensor, such as raised birthmarks, scars, tattoos;

• Pregnancy;

• Nursing mothers;

• Any skin scratch(es), damage, over dry, long nails on the measured finger;

• Unsuitable finger with the device might be excluded if recognized during the trial;

• Medication containing nitrates

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• Vital GlucoseDetect
11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.

Locations

Country	Name	City	State
Germany	Pfützner Science & Health Institute GmbH	Mainz	Rhineland-Palatinate

Sponsors (1)

Lead Sponsor	Collaborator
Sciema UG

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance and accuracy in glucose monitoring and other parameters	Performance and accuracy in monitoring glucose levels (in mg/dL) using the GlucoseDetect during a standardized meal experiment. Measurements (during the meal experiment) of the GlucoseDetectTM will be compared to the capillary blood glucose reference method YSI STAT 2300 (glucose in mg/dL).	210 min
Primary	Performance and accuracy in pO2 monitoring	Performance and accuracy in monitoring pO2 levels (in mmHg) using the GlucoseDetect during a standardized meal experiment. Measurements (during the meal experiment) of the GlucoseDetectTM will be compared to a patient monitor (pO2 (in mmHg).	210 min
Primary	Performance and accuracy in pulse monitoring	Performance and accuracy in monitoring the pulse (in beats/min) using the GlucoseDetect during a standardized meal experiment. Measurements (during the meal experiment) of the GlucoseDetectTM will be compared to a patient monitor (pulse (in beats/min).	210 min